• Type 2 diabetes mellitus imposes a considerable and increasing burden on healthcare resources, 1, 2 largely as a result of long-term complications associated with hyperglycaemia.
largely as a result of long-term complications associated with hyperglycaemia.
• Therapy for type 2 diabetes mellitus therefore aims to achieve and maintain recommended targets for glycaemic control. 3, 4 • Long-term, add-on treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide was associated with sustained improvements in glycaemic control and cardiovascular risk factors, and progressive weight loss during at least 3 years of follow-up.
5
• The aim of this analysis was to estimate the cost-effectiveness of treatment with exenatide once weekly (EQW) compared with that of exenatide twice daily (BID) in patients with type 2 diabetes in the UK.
METHODS
• The published and validated IMS CORE Diabetes Model (CDM) 6, 7 was used to make 50-year projections of clinical and cost outcomes based on pooled DURATION-1 and DURATION-5 baseline patient characteristics and study results.
-These studies had similar methodology and were randomised comparisons of EQW and exenatide BID.
• The model simulates disease progression by combining 15
inter-dependent Markov-based sub-models to determine the occurrence and time to onset of diabetes-related complications, life years gained and quality-adjusted life years (QALYs); and also projects costs.
Base case assumptions
Simulation cohort:
• Pooled data from patients with type 2 diabetes mellitus managed with dietary modifi cation and exercise and/or oral antidiabetic medications enrolled in the 30-week DURATION-1 (N=295) • Baseline diabetes-related medical histories were based on data from the NICE CG87 cohort. 10, 11 -For diabetes complications not reported in the CG87 cohort, a baseline prevalence rate of zero was assumed.
Perspective of the analysis:
• The analysis has been conducted from the UK national health service payer perspective.
Time horizon:
• A 50-year time horizon was used.
Primary outcome:
• The cost-effectiveness of EQW compared with exenatide BID as measured by the incremental cost per QALY gained.
Patient characteristics at baseline:
• Table 1 shows pooled baseline characteristics of patients enrolled in DURATION-1 and DURATION-5.
Treatment pathway:
• Patients received by subcutaneous injection either EQW 2 mg or exenatide 10 μg BID for 5 years. After 5 years all patients were switched to insulin glargine for the remainder of the 50-year period or until death, whichever came fi rst.
Costs:
• Complication costs were derived when possible from the UK Prospective Diabetes Study (UKPDS). Remaining complication and drug costs were derived from published sources and expressed in 2010 UK Pounds.
-An annual discount rate of 3.5% was applied to both costs and outcomes, in line with NICE recommendations.
METHODS CONT.
Key treatment-associated changes:
• Projected effects of EQW and exenatide BID on key patient outcomes were determined using pooled data from DURATION-1 and DURATION-5 ( Table 2 ) applied for the fi rst year, then progressed according to data from the UKPDS or Framingham study.
Statistical analyses:
• Data were analysed both deterministically (base case results),
for which simulated cohorts of 1,000 patients were repeated through 1,000 iterations to generate results, and using probabilistic sensitivity analyses (PSA), which were performed for a cohort of 25,000 patients and 500 iterations.
-All results are presented as mean values with standard deviation (SD), standard error (SE) and/or 95% confi dence intervals (CIs). -Projected treatment group differences are expressed as EQW minus exenatide BID.
Sensitivity analyses
• Various deterministic sensitivity analyses were performed:
-The projected effect of EQW on glycated haemoglobin (HbA 1c ), body mass index (BMI), systolic blood pressure and lipids was adjusted to the upper and lower 95% confi dence interval (projected effects of exenatide BID were fi xed). -Data from each trial were considered individually. -Complication costs were varied up and down by 20%.
-Selected utility values were included or excluded.
RESULTS CONT.

RESULTS
• EQW treatment was projected to improve QALYs (Tables 3 and 4 ) and life expectancy [PSA: by 0.164 (95% CI: 0.065-0.258) years; deterministic analysis: Table 3 ] compared with exenatide BID.
• EQW was projected to be associated with delayed onset of any diabetes-related complication versus exenatide BID (Table 5 ).
• Due to the lower projected incidence of most diabetes-related complications during treatment with EQW (Figure 1) , and hence reduction in their treatment costs, EQW was projected to be associated with direct medical cost savings versus exenatide BID (Tables 3 and 4 ).
• EQW was therefore projected to be dominant versus exenatide BID.
• Results were robust to all deterministic sensitivity analyses (Table 4) . • The lower incidence of most diabetes-related complications in EQW-treated patients was projected to result in lower costs over a patient's lifetime with EQW when compared with exenatide BID.
• Limitations: Patients were switched to insulin glargine after fi ve years; intermediate end points (e.g. HbA 1c , systolic blood pressure, lipids, BMI) were used to project long-term outcomes; intervention effects were applied in the fi rst year only. 
